Johnson & Johnson has acquired medtech company Abiomed for $16.6 billion at $380 per share. Abiomed will now operate as a business unit within J&J’s medtech segment.
Read the full post on Becker's Hospital Review - Healthcare News
Johnson & Johnson completes $16.6B acquisition of medtech company
